Apogee therapeutics, inc.APGE.US Overview

US StockHealthcare

(No presentation for APGE)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

APGE Overall Performance

APGE AI Analysis & Strategy

APGE Recent Performance

0.23%

Apogee therapeutics, inc.

0.81%

Avg of Sector

-1.14%

S&P500

APGE PowerScanner

APGE Key Information

APGE Valuation Metrics

APGE Earnings Table

APGE Profile

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.